347740 — P&K Skin Research Center Co Balance Sheet
0.000.00%
- KR₩64bn
- KR₩24bn
- KR₩18bn
- 89
- 62
- 51
- 79
Annual balance sheet for P&K Skin Research Center Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 49,723 | 42,249 | 57,463 | 44,688 | 40,711 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,191 | 1,467 | 2,584 | 5,908 | 5,414 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 51,252 | 44,018 | 60,359 | 51,079 | 48,164 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,531 | 4,618 | 4,571 | 4,639 | 3,639 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 59,892 | 67,094 | 74,539 | 77,407 | 82,040 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,564 | 3,118 | 3,085 | 2,590 | 4,747 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 4,265 | 4,027 | 3,732 | 3,204 | 5,104 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 55,626 | 63,067 | 70,807 | 74,203 | 76,935 |
Total Liabilities & Shareholders' Equity | 59,892 | 67,094 | 74,539 | 77,407 | 82,040 |
Total Common Shares Outstanding |